

### General Information:

Plan Report ID Number: 20221209lig

Developer Name: Lille Group, Inc

Product Name(s): eScribeHOST

Version Number(s): 7

Certified Health IT

Product List (CHPL) ID(s): 15.02.05.3058.LILG.01.01.1.220214

Developer Real World Testing Page URL: <https://www.escribe.com/transparency-esh.html>

### Summary of Testing Methods:

Real World Testing was completed by third party testers per the RWT plans established by Lille Group, Inc. and approved by ACB. Testers were given arbitrary time frames to access the app and complete testing in accordance with an on-going testing approach. Testers were given two sets of log on credentials, one with a complete set of permissions to access all required patient data for testing, one without complete permissions to demonstrate inability to access protected information (170.315(b,e)). In addition, testers were given a set of instructions outlining all actions required to test each criterion completely.

Testers reported all results and findings along with screenshots and copies of downloaded files to the third party testing administrator for review and compilation of results. The testing administrator then converted tester's results to rate of success metric in line with the RWT plans.

### Summary of Key Findings:

As described in this report, all Real World Testing was conducted successfully with zero nonconforming results found. All testing was completed within the acceptable time frame of 24 working hours outlined in the RWT plans.

Each criterion was tested by 3 different testers evaluating 3 patient data sets, as outlined in the RWT plans. Using multiple third party testers to evaluate each criterion demonstrates continuity of results and real-world interoperability. Using multiple patient data sets demonstrates the real world use case of retrieving, modifying and exporting data for specified patients.

No non-conformities were discovered during testing. No deviations from the original testing plan were present. All results are within expected range of success.

Standards Updates via SVAP and/or USCDI:

Standard (and version)	USCDI v1
Updated certification criteria and associated product	b1, b2, e1, g9
Health IT Module CHPL ID	15.02.05.3058.LILG.01.01.1.220214
Method Used for standards update	Cures Update
Date of ONC ACB notification	12/21/2022
Date of customer notification (SVAP only)	N/A
Conformance Measure(s)	Rate of Success for: b1, b2, e1, g9
USCDI Updated certification criteria (and USCDI version)	b1, b2, e1, g9 - USCDI v1

Care Setting(s):

Care Setting	Justification
Cardiology Office	EscribeHost is marketed to cardiology practices and has been tested in accordance with our cardiology clientele. The care setting where patient information should be accessed, added, changed and exchanged is in the office among only professionals with appropriate permissions.

Metrics and Outcomes:

All tests are reported in the metric of rate of success. Rate of success is reported as the percentage of successful attempts to perform actions defined above out of total attempts to perform actions defined in RWT plans. All attempts are defined as successful if performed completely and in accordance with all specifications within a reasonable time, defined as one day (24 hours), or one working day (24 hours discounting weekends and holidays) for criteria relying on outside parties who do not operate on a constant basis (pharmacies, etc).

No additional software has been relied upon in the testing process to obtain results.

Test	Metric	Associated Criterion	Outcome	Challenges Encountered
Patient information can be accessed and edited on demand with appropriate permissions	Rate of Success	170.315 (b)(2)	100% Success	
Patient interventions can be accessed and edited on demand with appropriate permissions	Rate of Success	170.315(b)(2)	100% Success	
Patient problems can be accessed and edited on demand with appropriate permissions	Rate of Success	170.315(b)(2)	100% Success	
Patient medications can be accessed on demand with appropriate permissions	Rate of Success	170.315(b)(2)	100% Success	
Patient allergies can be accessed on demand with appropriate permissions	Rate of Success	170.315(b)(2)	100% Success	
Confirmed presence of all required fields/data in patient transition of care documents	Rate of Success	170.315(b)(1)	100% Success	
System responds to all required prescription requests	Rate of Success	170.315(b)(3)	100% Success	
Patient data can be exported on demand at any time for single or multiple patients	Rate of Success	170.315(b)(6)	100% Success	
Exported CQMs contain all required fields	Rate of Success	170.315(c)(1)	100% Success	
CQMs can be exported on	Rate of	170.315(c)(1)	100%	

demand at any time with appropriate permissions	Success		Success	
Lab Reports can be downloaded in human readable format on demand by users with appropriate permissions	Rate of Success	170.315(e)(1)	100% Success	Where applicable
Imaging Reports can be downloaded in human readable format on demand by users with appropriate permissions	Rate of Success	170.315(e)(1)	100% Success	Where applicable
Reports contain all required data	Rate of Success	170.315(e)(1)	100% Success	
Lab and Imaging Reports cannot be accessed by users without appropriate permissions	Rate of Success	170.315(e)(1)	100% Success	
Information can be accessed by a user with appropriate permissions via unique patient ID	Rate of Success	170.315(g)(7), 170.315(g)(9)	100% Success	

Key Milestones:

All Milestones are within the care setting of Cardiology Offices.

Milestone	Date/Timeframe
ACB approves RWT plans	January 2023
Lille Group, Inc. writes testing scripts	January 2023 (and previous test scripts applied from January 2022)
Testing is performed	February 2023 - October 2023
Results are recorded and supplied to testing authority	February 2023 - October 2023
Results are assessed and compiled	November 2023
Report template is created	November 2023
Report is completed with results and evaluations	December 2023

Report submitted for ACB review	January 2024
Report revised per ACB feedback	January 2024
Report posted to Lille Group, Inc. website	February 2024

#### Evaluation of Results:

Real World Testing (RWT) for EscribeHOST was conducted by three testers, and one backup tester, familiar with the application throughout 2023. Instructions were provided to third party testers on how to access the test environment, as were specific instructions on how to submit results were included in an introductory email. Testers were asked to proceed on their own schedule using arbitrary times and dates, record time spent on each test and to alert the test administrator when complete. Results were compiled by the test administrator and saved for later review. These results were converted by the test administrator to rate of success in accordance with the RWT plans. All results are supplied in this report as rate of success.

All third party testers were clear on expectations and testing time was well within established expectations set previously by internal testers, approximately 20 min per set of three patients per test for less than 1 hour of total testing time per testing session, excluding planned downtime per the RWT plan.

Testing results were clear and demonstrated each tester's facility with the EscribeHOST application as well as the applications functionality relative to generating desired results.

One instance of tester error arose during testing. This tester was given more specific instructions to proceed and tested independently supplying correct and expected results.

Results were expected in the 80-100% range for rate of success, and all results fell within this range.

Testing successfully demonstrated real world usability on an on-going basis of EscribeHost in reference to all certified criteria.